Markets & Regulations

Agilent is splitting into two companies

Agilent splits up to create two separate businesses

Agilent Technologies has officially separated its biopharma service offerings from its electric measurement group to create two separate companies, the life science portion of which is expected to bring in about $3.9B in FY2013.

Fast track status for Novartis MAb Bimagrumab

FDA Grants Novartis Biologic Breakthrough Status

By Dan Stanton

A third Novartis biopharmaceutical has received breakthrough designation status from the FDA allowing ‘fast-track’ development and review without compromising safety, the company says.

Follow us

Products

View more

Webinars